Evidence map›Paper›PMID 38970764›Full record

ArticleCurrent oncology reports2024

Biomarkers in the Immuno-oncology Interface of Triple Negative Breast Cancer: A Scoping Review with Perioperative Considerations.

Laura Smith, John Saganty, Patrice Forget

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Current oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laura SmithAberdeen Royal Infirmary, Foresterhill Rd, Aberdeen, AB25 2ZN, UK. lasmith574@btinternet.com.ORCID http://orcid.org/0000-0002-5851-8211
John SagantyRoyal Stoke University Hospital, Newcastle Rd, Stoke-on-Trent, ST4 6QG, UK.ORCID http://orcid.org/0000-0002-3523-227X
Patrice ForgetAberdeen Royal Infirmary, Foresterhill Rd, Aberdeen, AB25 2ZN, UK.ORCID http://orcid.org/0000-0001-5772-8439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewIdentification of biomarkers for immunotherapy treatment in triple negative breast cancer remains crucial for improving outcomes and optimising regimes, particularly in the perioperative setting. There is a need to conduct a scoping review to provide an overview of current research, explore the wider context, and highlight future research considerations in this field. RECENT

findingsThe most commonly assessed biomarkers are PD-L1, TILs and CD8 + cells with correlation to outcomes mainly focused on survival. There is a growing interest in evaluating genetic markers. Conclusions are currently limited by knowledge gaps around contextual factors. Important areas of focus for future research include a greater understanding of complex cellular, genetic and metabolic interactions in the perioperative tumour microenvironment, including patient-specific immune profiles. An important challenge remains elucidating the clinical significance of the immunological effects of interventions at each stage of the perioperative period, including the use of anaesthetic agents.

Indexed as

Biomarkers, TumorTriple Negative Breast NeoplasmsB7-H1 AntigenCD8-Positive T-LymphocytesFemaleHumansImmunotherapyLymphocytes, Tumor-InfiltratingPerioperative PeriodTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanBiomarkersImmunotherapyOutcomesPerioperativeTriple negative breast cancer

Identifiers

PMID38970764

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.